Oxford Nanopore Technologies (ONT) Stock Overview
Engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ONT Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Oxford Nanopore Technologies plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.18 |
| 52 Week High | UK£2.25 |
| 52 Week Low | UK£0.96 |
| Beta | 0.83 |
| 1 Month Change | -18.60% |
| 3 Month Change | -5.29% |
| 1 Year Change | 16.11% |
| 3 Year Change | -40.00% |
| 5 Year Change | n/a |
| Change since IPO | -80.71% |
Recent News & Updates
Recent updates
Getting In Cheap On Oxford Nanopore Technologies plc (LON:ONT) Might Be Difficult
Jan 11
Oxford Nanopore Technologies plc's (LON:ONT) Stock Retreats 25% But Revenues Haven't Escaped The Attention Of Investors
Sep 13We Think Oxford Nanopore Technologies (LON:ONT) Can Afford To Drive Business Growth
Aug 21Oxford Nanopore Technologies plc (LON:ONT) Looks Just Right With A 26% Price Jump
Jul 15Here's Why We're Not Too Worried About Oxford Nanopore Technologies' (LON:ONT) Cash Burn Situation
May 09
Focusing On Biopharma And Industrial Markets Will Diversify Revenue Streams
Targeting high-growth biopharma and industrial segments diversifies revenue, mitigating traditional funding risks and driving significant revenue growth.Oxford Nanopore Technologies plc's (LON:ONT) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Feb 28The Price Is Right For Oxford Nanopore Technologies plc (LON:ONT)
Dec 19Investors Appear Satisfied With Oxford Nanopore Technologies plc's (LON:ONT) Prospects As Shares Rocket 33%
Sep 20Revenues Tell The Story For Oxford Nanopore Technologies plc (LON:ONT) As Its Stock Soars 30%
Jul 23What You Can Learn From Oxford Nanopore Technologies plc's (LON:ONT) P/SAfter Its 25% Share Price Crash
Apr 26Oxford Nanopore Technologies plc (LON:ONT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 09Oxford Nanopore Technologies plc's (LON:ONT) Share Price Matching Investor Opinion
Mar 08Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Jul 12With Oxford Nanopore Technologies plc (LON:ONT) It Looks Like You'll Get What You Pay For
May 14Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Apr 06Companies Like Oxford Nanopore Technologies (LON:ONT) Can Afford To Invest In Growth
Dec 22New Forecasts: Here's What Analysts Think The Future Holds For Oxford Nanopore Technologies plc (LON:ONT)
Sep 19We Think Oxford Nanopore Technologies (LON:ONT) Can Easily Afford To Drive Business Growth
Sep 16Shareholder Returns
| ONT | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -4.7% | -2.0% | -2.1% |
| 1Y | 16.1% | 11.6% | 21.6% |
Return vs Industry: ONT exceeded the UK Life Sciences industry which returned 11.6% over the past year.
Return vs Market: ONT underperformed the UK Market which returned 21.6% over the past year.
Price Volatility
| ONT volatility | |
|---|---|
| ONT Average Weekly Movement | 8.2% |
| Life Sciences Industry Average Movement | 10.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: ONT's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ONT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,335 | Francis Van Parys | nanoporetech.com |
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company also provides PromethION 2 Solo, PromethION 2, PromethION 24, and PromethION 48.
Oxford Nanopore Technologies plc Fundamentals Summary
| ONT fundamental statistics | |
|---|---|
| Market cap | UK£1.17b |
| Earnings (TTM) | -UK£145.20m |
| Revenue (TTM) | UK£223.90m |
Is ONT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONT income statement (TTM) | |
|---|---|
| Revenue | UK£223.90m |
| Cost of Revenue | UK£87.50m |
| Gross Profit | UK£136.40m |
| Other Expenses | UK£281.60m |
| Earnings | -UK£145.20m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 19, 2026
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 60.92% |
| Net Profit Margin | -64.85% |
| Debt/Equity Ratio | 0% |
How did ONT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 18:28 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oxford Nanopore Technologies plc is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Blanka Porkolab | Barclays |
| Odysseas Manesiotis | Berenberg |